Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 7/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 5/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4492863 | 0.94 | P2RX3 (0.43) | GSK3BCYP2D6P2RX3ADRA1ATAAR1 | |
| SCHEMBL4489193 | 0.89 | GSK3B (0.43) | GSK3B | |
| SCHEMBL4484424 | 0.86 | GSK3B (0.46) | GSK3BCYP2D6 | |
| SCHEMBL4484075 | 0.82 | GSK3B (0.44) | GSK3BCYP2D6 | |
| SCHEMBL4588003 | 0.82 | GSK3B (0.42) | GSK3BCYP2D6P2RX3 | |
| SCHEMBL4493707 | 0.79 | PIK3CD (0.45) | GSK3B | |
| SCHEMBL4473538 | 0.79 | PIK3CD (0.45) | GSK3B | |
| SCHEMBL3996514 | 0.79 | GSK3B (0.43) | GSK3BCYP2D6MTNR1AMTNR1B | |
| SCHEMBL4498677 | 0.78 | PIK3CB (0.45) | GSK3B | |
| SCHEMBL4498668 | 0.78 | GSK3B (0.49) | GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7608624-B2 | 1-[alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-pyridinyl-imidazo[1,2-a]pyrimidin-5(1h)-one derivatives | SANOFI-AVENTIS (FR) | 2009-10-27 | — | — | US | claimed |
| US-20060148825-A1 | 1-[Alkyl], 1-[(heteroaryl) alkyl] and 1-[(Aryl)alkyl]-7-pyridinyl-imidazo[1,2-a]pyrimidin-5(1H)-one derivatives | SANOFI-AVENTIS (FR) | 2006-07-06 | — | — | US | claimed |
| US-7067521-B2 | 1-[alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7pyridinyl-imidazo[1,2-alpha]pyrimidin-5(1H)-one derivatives | SANOFI-AVENTIS (FR) | 2006-06-27 | — | — | US | claimed |
| EP-1315730-B1 | 1-(ALKYL), 1-[(HETEROARYL)ALKYL] AND 1-[(ARYL)ALKYL]-7-PYRIDINYL-IMIDAZO(1,2-A)PYRIMIDIN-5(1H)-ONE DERIVATIVES | SANOFI SYNTHELABO (FR) | 2004-06-30 | — | — | EP | claimed |
| US-7608624-B2 | 1-[alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-pyridinyl-imidazo[1,2-a]pyrimidin-5(1h)-one derivatives | SANOFI-AVENTIS (FR) | 2009-10-27 | — | — | US | disclosed |
| US-20060148825-A1 | 1-[Alkyl], 1-[(heteroaryl) alkyl] and 1-[(Aryl)alkyl]-7-pyridinyl-imidazo[1,2-a]pyrimidin-5(1H)-one derivatives | SANOFI-AVENTIS (FR) | 2006-07-06 | — | — | US | disclosed |
| US-7067521-B2 | 1-[alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7pyridinyl-imidazo[1,2-alpha]pyrimidin-5(1H)-one derivatives | SANOFI-AVENTIS (FR) | 2006-06-27 | — | — | US | disclosed |
| EP-1315730-B1 | 1-(ALKYL), 1-[(HETEROARYL)ALKYL] AND 1-[(ARYL)ALKYL]-7-PYRIDINYL-IMIDAZO(1,2-A)PYRIMIDIN-5(1H)-ONE DERIVATIVES | SANOFI SYNTHELABO (FR) | 2004-06-30 | — | — | EP | disclosed |
| EP-1315730-A1 | 1-(ALKYL), 1-[(HETEROARYL)ALKYL] AND 1-[(ARYL)ALKYL]-7-PYRIDINYL-IMIDAZO(1,2-A)PYRIMIDIN-5(1H)-ONE DERIVATIVES | SANOFI-SYNTHELABO (FR) | 2003-06-04 | — | — | EP | disclosed |
| WO-2002018385-A1 | 1-[ALKYL], 1-[(HETEROARYL)ALKYL] AND 1-[(ARYL)ALKYL]-7-PYRIDINYL-IMIDAZO[1,2-a]PYRIMIDIN-5(1H)-ONE DERIVATIVES | SANOFI-SYNTHELABO (FR) | 2002-03-07 | — | — | WO | disclosed |
| EP-1184384-A1 | 1-(Alkyl), 1-((heteroaryl)alkyl) and 1-((aryl)alkyl)-7-pyridin-4-ylimidazo(1,2a)pyrimidin-5(1H)-one derivatives | SANOFI-SYNTHELABO (FR) | 2002-03-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148825-A1 | 1-[Alkyl], 1-[(heteroaryl) alkyl] and 1-[(Aryl)alkyl]-7-pyridinyl-imidazo[1,2-a]pyrimidin-5(1H)-one derivatives | PSEN1, PSEN2, SNCA | GSK3B 4408/4885CYP2D6 1406/4885P2RX3 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.